Gil Blum
Stock Analyst at Needham
(4.63)
# 890
Out of 5,036 analysts
722
Total ratings
42.3%
Success rate
13.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gil Blum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Reiterated: Buy | $82 | $54.00 | +51.85% | 44 | Oct 5, 2026 | |
| FATE Fate Therapeutics | Reiterated: Hold | n/a | $2.29 | - | 25 | Oct 5, 2026 | |
| NKTX Nkarta | Reiterated: Buy | $11 | $2.31 | +376.19% | 24 | Oct 5, 2026 | |
| AUTL Autolus Therapeutics | Reiterated: Buy | $10 | $1.79 | +458.66% | 53 | Oct 2, 2026 | |
| ARTV Artiva Biotherapeutics | Reiterated: Buy | $41 | $7.27 | +463.96% | 17 | Oct 1, 2026 | |
| CELC Celcuity | Reiterated: Buy | $140 → $134 | $71.25 | +88.07% | 35 | Sep 30, 2026 | |
| IMMX Immix Biopharma | Reiterated: Buy | $21 → $30 | $9.64 | +211.20% | 3 | Sep 29, 2026 | |
| RNAC Cartesian Therapeutics | Reiterated: Buy | $40 | $6.75 | +492.59% | 38 | Sep 29, 2026 | |
| SRPT Sarepta Therapeutics | Reiterated: Sell | n/a | $17.31 | - | 57 | Sep 28, 2026 | |
| ABSI Absci | Reiterated: Buy | $11 | $10.27 | +7.11% | 15 | Sep 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $9 | $2.48 | +262.90% | 51 | Sep 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $44 | $8.61 | +411.03% | 7 | Sep 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.2754 | - | 19 | Sep 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $56 | $26.89 | +108.26% | 1 | Aug 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $4.39 | +173.35% | 50 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $0.3501 | +756.90% | 35 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $6.92 | +174.57% | 8 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $29.64 | +153.04% | 23 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $1.21 | +230.58% | 36 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $4.63 | +72.79% | 30 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 | $22.60 | +50.44% | 48 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $5.86 | - | 28 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.40 | - | 25 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $5.69 | n/a | 15 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $22.41 | n/a | 14 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $80.11 | n/a | 10 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.000001 | n/a | 6 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | - | n/a | 5 | Apr 6, 2022 |
CRISPR Therapeutics AG
Oct 5, 2026
Reiterated: Buy
Price Target: $82
Current: $54.00
Upside: +51.85%
Fate Therapeutics
Oct 5, 2026
Reiterated: Hold
Price Target: n/a
Current: $2.29
Upside: -
Nkarta
Oct 5, 2026
Reiterated: Buy
Price Target: $11
Current: $2.31
Upside: +376.19%
Autolus Therapeutics
Oct 2, 2026
Reiterated: Buy
Price Target: $10
Current: $1.79
Upside: +458.66%
Artiva Biotherapeutics
Oct 1, 2026
Reiterated: Buy
Price Target: $41
Current: $7.27
Upside: +463.96%
Celcuity
Sep 30, 2026
Reiterated: Buy
Price Target: $140 → $134
Current: $71.25
Upside: +88.07%
Immix Biopharma
Sep 29, 2026
Reiterated: Buy
Price Target: $21 → $30
Current: $9.64
Upside: +211.20%
Cartesian Therapeutics
Sep 29, 2026
Reiterated: Buy
Price Target: $40
Current: $6.75
Upside: +492.59%
Sarepta Therapeutics
Sep 28, 2026
Reiterated: Sell
Price Target: n/a
Current: $17.31
Upside: -
Absci
Sep 23, 2026
Reiterated: Buy
Price Target: $11
Current: $10.27
Upside: +7.11%
Sep 16, 2026
Upgraded: Buy
Price Target: $9
Current: $2.48
Upside: +262.90%
Sep 11, 2026
Reiterated: Buy
Price Target: $44
Current: $8.61
Upside: +411.03%
Sep 2, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.2754
Upside: -
Aug 21, 2026
Initiated Coverage: Buy
Price Target: $56
Current: $26.89
Upside: +108.26%
Aug 12, 2026
Reiterated: Buy
Price Target: $12
Current: $4.39
Upside: +173.35%
Aug 11, 2026
Reiterated: Buy
Price Target: $3
Current: $0.3501
Upside: +756.90%
Aug 7, 2026
Reiterated: Buy
Price Target: $19
Current: $6.92
Upside: +174.57%
Aug 6, 2026
Reiterated: Buy
Price Target: $75
Current: $29.64
Upside: +153.04%
Aug 5, 2026
Reiterated: Buy
Price Target: $4
Current: $1.21
Upside: +230.58%
Aug 5, 2026
Reiterated: Buy
Price Target: $8
Current: $4.63
Upside: +72.79%
Aug 4, 2026
Reiterated: Buy
Price Target: $34
Current: $22.60
Upside: +50.44%
Nov 7, 2025
Reiterated: Hold
Price Target: n/a
Current: $5.86
Upside: -
Oct 24, 2025
Rated: Hold
Price Target: n/a
Current: $1.40
Upside: -
Dec 27, 2024
Rated: Hold
Price Target: n/a
Current: $5.69
Upside: n/a
Dec 7, 2022
Reiterated: Buy
Price Target: $6
Current: $22.41
Upside: n/a
Aug 25, 2022
Rated: Hold
Price Target: n/a
Current: $80.11
Upside: n/a
Jun 3, 2022
Rated: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Apr 6, 2022
Reiterated: Buy
Price Target: $6
Current: -
Upside: n/a